Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antimicrobial Drug Reviews Would Need To Consider “Resistance” Under Bill

Executive Summary

Impact on drug-resistant microbes would be a factor considered during the review of antimicrobial drug applications under legislation introduced in the House Sept. 27 by Reps. Jim Matheson, D-Utah, and Mike Ferguson, R-N.J
Advertisement

Related Content

Antibiotic Resistance Gets Attention Of FDA, Congress
Antibiotics Need REMS For Public, Not Patient, Safety Reasons, IDSA Says
Antibiotics Need REMS For Public, Not Patient, Safety Reasons, IDSA Says
FDA Found Answer To Vibativ Dilemma Of Teratogenicity Vs. Microbial Resistance In REMS
FDA Found Answer To Vibativ Dilemma Of Teratogenicity Vs. Microbial Resistance In REMS
Antimicrobial Resistance Rallies Calls For Active FDA, R&D Incentives
Under Waxman’s microscope
Antibiotic Trial Standards To Be Revised By FDA Under Congressional Mandate
Antibiotic Trial Standards To Be Revised By FDA Under Congressional Mandate
Antibacterial Final Rule Defers To Doctors; Labeling Will Emphasize Testing
Advertisement
UsernamePublicRestriction

Register

PS048879

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel